Clinical trials: System Lupus Erythematosus
Systemic Lupus Erythematosus, Systemic Sclerosis
Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases
A subset of autoimmune diseases (ADs) in children and young adults are life-threatening and unresponsive to conventional treatments.
- Trial name
- NCT05029336
- Testing
- Depletion of CD3/CD19 in an autologous stem cell transplant
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stephan Grupp MD PhD
Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
The purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active cutaneous manifestations of lupus erythematosus with or without systemic…
- Trial name
- ELOWEN-1 (NCT07332481)
- Testing
- Enpatoran, Standard of care (SoC)
- Where
- 60 sites in United States, Australia and 14 more
- Volunteers
- 202 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Rheumatoid Arthritis, Systemic Lupus Erythematosus
A Trial in Healthy Adult Participants and Adults With Autoimmune Disease to Test How HBM7020 is Tolerated and Absorbed in the Body
This first-in-human study evaluates the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of HBM7020.
- Conditions
- Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis, Sjögren's Disease
- Trial name
- NCT07649265
- Testing
- HBM7020
- Where
- Australia
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Alopecia Areata, Depressive Episode
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
This study series consists of four related studies and aims to explore and describe many important elements of alopecia areata over three key areas: (1) the current epidemiology of alopecia areata, (2) the prevalence and…
- Conditions
- Alopecia Areata, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders
- Trial name
- NCT04239521
- Testing
- Exposure of interest (studies 2 & 3).
- Where
- United Kingdom
- Volunteers
- 51,955 people
- Sponsor
- Momentum Data
Lupus Erythematosus, Systemic
A Safety and Tolerability Study of MEDI-570 in Systemic Lupus Erythematosus
The purpose of this study is to evaluate the safety and tolerability of MEDI-570 in adult subjects with moderately to severely active systemic lupus erythematosus (SLE).
- Trial name
- NCT01127321
- Testing
- MEDI-570 0.03 MG, MEDI-570 0.1 MG, MEDI-570 0.3 MG
- Where
- 17 sites in United States, Canada and 3 more
- Volunteers
- 44 people
- Sponsor
- MedImmune LLC
Sjögrens Disease, Systemic Lupus Erythematosus
Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease
The purpose of this study is to demonstrate the comparability of ianalumab exposure following the sub-cutaneous (s.c.) administration of one injection of 300 mg/2 mL auto-injector (AI) versus two injections of 150 mg/1 mL…
- Conditions
- Sjögrens Disease, Systemic Lupus Erythematosus, Rheumatoid Arthritis
- Trial name
- NCT06293365
- Testing
- VAY736 1ml PFS, VAY736 2 ml PFS, VAY736 2ml AI
- Where
- 37 sites in United States, Argentina and 6 more
- Volunteers
- 155 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Lupus Erythematosus, Lupus Nephritis
CHT105 for the Treatment of Refractory Lupus Nephritis
Systemic lupus erythematosus (SLE) is the most common systemic autoimmune disease in China. The kidneys are the organ most frequently affected in SLE and a major cause of mortality among SLE patients.
- Trial name
- NCT07517536
- Testing
- anti-CD19/70 CAR T cells (CHT105)
- Where
- China
- Volunteers
- 14 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Systemic Lupus Erythematosus
BLYS and IFN in SLE
This protocol tests whether changes in BLyS or IFN can be detected in a normal immune response to a vaccine and, if so, whether the response differs between those with lupus and healthy controls.
- Trial name
- NCT00611611
- Testing
- fluzone, pneumovax
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Lupus Nephritis, Lupus Erythematosus, Systemic
Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis
The investigators study the efficacy and safety of tacrolimus in the treatment of membranous nephritis secondary to systemic lupus erythematosus.
- Trial name
- NCT00125307
- Testing
- tacrolimus
- Where
- Hong Kong
- Volunteers
- 20 people
- Sponsor
- Chinese University of Hong Kong
Rheumatoid Arthritis, Systemic Lupus Erythematosus
Ascension® Post- Approval Study; PyroCarbon Metacarpophalangeal Total Joint Prosthesis
This study is a non-randomized, consecutive enrollment, one-year post-approval study of patients who are treated with the Ascension® MCP.
- Conditions
- Rheumatoid Arthritis, Systemic Lupus Erythematosus, Osteoarthritis, Post-traumatic Arthritis
- Trial name
- MCP (NCT02408471)
- Testing
- Ascension® MCP Finger Implant
- Where
- 9 sites in United States
- Volunteers
- 97 people
- Sponsor
- Smith & Nephew, Inc.
Lupus Nephritis
A Study to Evaluate the Efficacy and Safety of Tacrolimus With Steroid in Korean Lupus Nephritis Patients
This study is to evaluate efficacy and safety of tacrolimus with steroid by observing remission rate at 24 weeks in lupus nephritis patients who are non-responders to steroid monotherapy.
- Trial name
- APPLE (NCT01316133)
- Testing
- tacrolimus
- Where
- 7 sites in South Korea
- Volunteers
- 37 people
- Sponsor
- Astellas Pharma Korea, Inc.
Systemic Lupus Erythematosus
Reducing Disparities in Medication Adherence in SLE
This is a pilot study to assess the feasibility of using Surescripts refill data during the clinical encounter to improve medication adherence in patients with systemic lupus erythematosus
- Trial name
- NCT03738826
- Testing
- Behavioral Intervention
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- Duke University
Systemic Lupus Erythematosus, Interferon Deficiency
Type 1 Interferon Induced Changes to Exercise Adaptations in Systemic Lupus Erythematosus Patients
Investigating the physiological effects of the interferons type 1 and 2 (IFNs), and the cytokines Interleukin 6 (IL-6) and tumor necrosis factor (TNF) on the adaptive changes to exercise in patients with systemic lupus…
- Trial name
- LUPEX (NCT05478018)
- Testing
- High Intensity Interval Training (HIIT)
- Where
- Denmark
- Volunteers
- 55 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Systemic Lupus Erythematosus (SLE), Lupus Nephritis
Lupus Landmark Study: A Prospective Registry and Biorepository
The purpose of the registry and biorepository is to provide a mechanism to store clinical data, linked biospecimens and molecular data to support the conduct of future research on Systemic Lupus Erythematosus (SLE), including…
- Conditions
- Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Neuropsychiatric Systemic Lupus Erythematosus
- Trial name
- NCT05934149
- Where
- 25 sites in United States, Canada
- Volunteers
- 3,500 people
- Sponsor
- Lupus Research Alliance
Systemic Lupus Erthematosus, Lupus Glomerulonephritis
Renal Resistive Index as an Indicator of Lupus Nephritis Severity and Systemic Lupus Activity
The study explores the role of the colour Doppler scanning of the renal arteries and its relation to the degree of disease affection in lupus nephritis
- Conditions
- Systemic Lupus Erthematosus, Lupus Glomerulonephritis, Lupus Flare
- Trial name
- NCT06757725
- Testing
- colour doppler of the renal artery and measurement of resistive index
- Where
- Egypt
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Kasr El Aini Hospital
Systemic Lupus Erythematosus (SLE)
CYCLONES - CYClophosphamide LOw Dose and No Extra Steroid
Glucocorticoids (GC) use has increased survival of patients with systemic lupus erythematosus (SLE), particularly in cases of nephritis and a more significant improvement to 80% with the introduction of therapy combined with…
- Trial name
- CYCLONES (NCT03492255)
- Testing
- Cyclophosphamide, Methylprednisolone, Prednisone
- Where
- 2 sites in Brazil
- Volunteers
- 49 people
- Sponsor
- University of Sao Paulo General Hospital
Lupus Erythematosus, Systemic
Pilot Study to Investigate Contemplative Intervention in Lupus Patients
The study tests whether contemplative-based intervention can modify pathogenic processes in participants with Lupus. Techniques such as meditation, mindfulness and yoga may have an impact on the disease and may decrease…
- Trial name
- LUPP (NCT03103243)
- Testing
- Mindfulness Based Group Sessions
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Immune Thrombocytopenic Purpura ( ITP ), Systemic Lupus Erythematosus (SLE)
Modeling the Early Stages of Autoimmunity Through the Study of Immunological Thrombocytopenic Purpura and Juvenile Lupus
Immunologic thrombocytopenic purpura (ITP) in children is a pre-lupus condition if associated with the presence of anti-nuclear antibodies (ANA), providing a unique model for understanding the natural history of autoimmunity…
- Trial name
- PRELUDE (NCT07680010)
- Testing
- Blood sampling baseline and M3, Monitoring for SLE, Procedure/Surgery: Blood sampling baseline and M3 then each 6 months until 48 months
- Where
- 2 sites in France
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Lupus Erythematosus, Systemic
An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
This Phase II, multicenter, open-label extension (OLE) study will evaluate the long-term safety and efficacy of GDC-0853 in participants with systemic lupus erythematosus (SLE) who have completed Study GA30044 (NCT02908100) up to…
- Trial name
- NCT03407482
- Testing
- GDC-0853
- Where
- 53 sites in United States, Argentina and 9 more
- Volunteers
- 160 people
- Sponsor
- Genentech, Inc.
Lupus Nephritis
Lupus Flares and Histological Renal Activity at the End of the Treatment (LuFla)
At this moment, the duration of the treatment in Proliferative Lupus Nephritis has not been determined. Almost 30 percent of patients in total remission during or after a treatment, will relapse in the first 5 years.
- Trial name
- LuFla (NCT02313974)
- Testing
- Renal Biopsy
- Where
- Argentina
- Volunteers
- 36 people
- Sponsor
- Hospital de Clinicas José de San Martín
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.